Published in final edited form as:

Bioorg Med Chem Lett. 2007 September 15; 17(18): 5063–5067. doi:10.1016/j.bmcl.2007.07.014.

Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells

M. Kyle Hadden and Brian S. J. Blagg

Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, Kansas 66045-7563

Abstract

Small molecules based upon natural product dimers that exhibit cytotoxic activity were synthesized and evaluated for their anti-proliferative activity in human breast cancer cell lines. A central isophthalic core structure linking aromatic amines containing 3,5-disubstitutions produced the most active compounds. This series of compounds was found to be more active against the estrogen receptor positive cell line MCF-7 than the estrogen receptor negative cell line, SKBr3.

Numerous proteins responsible for cell proliferation and differentiation exist either as hetero or homodimers or become activated through dimerization as the initial step in their respective signaling cascade. For example, the receptor tyrosine kinases VEGF and PDGF are important cellular growth factors activated as homodimers by ligand binding.^{1–2} Certain cytokines, including human growth hormone and erythropoietin, have been shown to bind simultaneously to two receptors and create a receptor-ligand-receptor complex.^{3–4} The estrogen receptor isoforms ER α and ER β form homo or heterodimers upon ligand binding.^{5–7} Hsp90, a molecular chaperone responsible for the maturation of numerous signaling proteins, exists predominantly as a cytosolic homodimer.⁸ The existence of such dimeric proteins as therapeutic targets suggests that dimeric small molecules can be appropriate building blocks for disruption of these and related protein complexes.

Many natural product dimers and their analogues have been studied for cytotoxic activity. Torreyanic acid, a quinone dimer, demonstrated cytotoxic activity in numerous human cancer cell lines and was determined to exhibit selective toxicity against cell lines that demonstrate susceptibility to agonists of protein kinase C.⁹ The dicerandrols were isolated and characterized as 2,2'-dimeric tetrahydroxanthones that display potent cytotoxic activity against lung and colon cancer cell lines.¹⁰ Coumermycin A1, a dimeric member of the coumarin family of antibiotics exhibits potent anti-proliferative activity in human breast cancer cell lines and structural analogues exhibit low micromolar anti-proliferative activity.^{11–12} In addition to these representative examples of naturally occurring dimers, numerous groups have synthesized dimeric structures of natural products in an effort to simultaneously inhibit both monomeric units of a dimeric protein. Several series of artemisinin-derived trioxane dimers have yielded derivatives that demonstrate submicromolar anti-proliferative activity.^{13–16} Geldanamycin dimers,¹⁷ estrogen dimers,¹⁸ and nonsteroidal bifunctional dimers¹⁹ that mimic tamoxifen have been prepared and retain potent anti-proliferative activity against various breast cancer cell lines. Based upon the dimeric nature of these compounds we sought to identify and optimize a simple scaffold that exhibits anti-proliferative activity against human

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

breast cancer cells. In particular, we desired a small molecule dimer structurally related to the coumermycin A1 aglycon.

Coumermycin A1 (Figure 1) is a natural product dimer that contains the general structure of novobiocin linked at the 2- and 4-positions of the central 3-methyl pyrrole bisester. We chose to prepare dimeric compounds that linked simplified amines mimicking the coumarin ring of coumermycin A1 through 5- or 6-membered aryl rings that were closely related to that of the central pyrrole. The diacids and amines used in the preparation of these analogues were chosen to investigate the role of hydrogen bonding, lipophilicity, and steric features important for anti-proliferative activity.

The first series of dimeric analogues was synthesized in an effort to optimize the aromatic appendages connected to the central diacid. This series contained 2,5-pyridine dicarboxylic acid (**A**, Figure 2) as the central unit and was coupled with a variety of amines that contained hydrophobic, hydrophilic, and hydrogen-bonding substituents (**DM1–DM17**). A second series contained 3,4-ethylenedioxyaniline (**1**, Figure 3) and was coupled to various diacids that represented analogues of the core acid (**DM18–DM27**). These dimers were prepared using the protocol shown in Scheme 1.²⁰

The analogues prepared via this protocol (**DM1–DM27**, Table 1) were tested for their anti-proliferative activity against two distinct human breast cancer cell lines, an estrogen receptor positive cell line, MCF-7, and an estrogen receptor negative, Her2 over-expressing cell line, SKBr3. The MTS cell proliferation kit (Promega) was utilized to determine cell viability following a 72 hour incubation of the compound in each cell line as described previously.²¹ In this assay, a novel tetrazolium dye (MTS) is bio-reduced by dehydrogenase enzymes in viable cells into a soluble formazan product, the absorbance of which is directly proportional to the number of living cells present. Coumermycin A1 was used as a positive control in these assays and the IC₅₀ values obtained were comparable to those previously reported.¹² Each dimer was incubated with the dye at the highest concentration tested in the anti-proliferative assays as a control for potential dimer-induced reduction.

Of this initial series that contained the 2,5-pyridine dicarboxylic acid as the central structure, only **DM5**, **DM10**, and **DM13** exhibited anti-proliferative activity in both cell lines (Table 1). The most active compound, **DM5** (IC₅₀ = 4.1 and 2.3 μ M in MCF-7 and SKBr3 cells, respectively), incorporated the 3,5-dichloroaniline side chains. **DM13**, which contained a single chlorine in the 3-position on the aniline, exhibited an ~7-fold reduction in anti-proliferative activity, suggesting a chlorine at each position is important for optimal activity.

Only one compound in the second series utilizing 3,4-ethylenedioxyaniline as the amine, **DM27**, exhibited anti-proliferative activity in this assay. Interestingly, this compound was only active in MCF-7 cells, suggesting the potential for future development of this scaffold as a cell-type specific inhibitor.

Based on the anti-proliferative activity of **DM5**, we synthesized a third series of dimers that incorporated the most active amine (**5**) with varying diacids (**DM28–DM35**, Table 2) in an attempt to further optimize the central moiety. Interestingly, the active compounds observed in this series contained variations of isophthalic acid (**DM28**, **DM29**, and **DM35**), suggesting that orientation of the anilines is important for the inhibition of cell growth. While the selectivity of **DM27** for MCF-7 cells was lost when the 3,4-ethylenedioxyaniline was replaced with aniline **5** (**DM29**), the overall anti-proliferative activity was increased ~3-fold. In addition, the three active dimers were 2- to 5-fold more active against the MCF-7 cell line.

Based upon the increased anti-proliferative activity associated with the central isophthalic core structure, we expanded the amines coupled to these diacids to give rise to a fourth series of

dimers (**DM36–DM53**). As expected, this series contained numerous dimers with anti-proliferative activity (Table 3). Two anilines (**4** and **6**) that were inactive in the original series of dimers demonstrated anti-proliferative activity when coupled with isophthalic acid derivatives. In addition, the dimer containing 3,5-dichloroaniline coupled to isophthalic acid (**DM35**) was 25-fold more active than the corresponding dimer containing a single chlorine atom (**DM41**), further supporting the importance of substituents in both positions for optimal activity. All dimers in this series were more active against MCF-7 than SKBr3 cells, consistent with the trend observed with the previous generations of compounds.

A final generation of dimers that incorporated anilines with varying substituents at the 3- and 5-positions (**19–21**) coupled with the four active diacids (**A, I–K**) was synthesized and evaluated (Table 4). These anilines were chosen based upon the size, hydrogen bonding, and electronic capabilities of the moieties at these two positions. This series produced no discernible structure-activity relationships for the 3,5-disubstituted anilines. Only **DM65**, containing 3,5-dimethylaniline linked through isophthalic acid exhibited anti-proliferative activity ($IC_{50} = 2.1$ and $12.2 \mu M$ for MCF-7 and SKBr3, respectively) comparable to the most active compounds from the previous series. Because chlorine and methyl groups are generally considered isosteric,²² these data suggest that the size of the substituents at these two positions is a determining factor for optimal activity.

In conclusion, a dimeric small molecule scaffold that displayed anti-proliferative activity was explored for the purpose of generating more efficacious compounds. The synthesis and evaluation of several generations of dimeric compounds provided structure-activity relationships for this series, indicating a central isophthalic core linking aromatic amines containing 3,5-disubstitutions are important for anti-tumor activity. Several compounds exhibited low micromolar activity and these dimers were generally more effective against MCF-7 cells, compared to SKBr3 cells.

Acknowledgements

The authors gratefully acknowledge support of this project by the NIH (R01 CA114393 and P50 GM069663).

References

1. Schlessinger J. Cell 2000;103:211. [PubMed: 11057895]
2. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Cell 1997;91:695. [PubMed: 9393862]
3. Kossiakoff AA, de Vos AM. Adv Protein Chem 1998;52:67. [PubMed: 9917918]
4. Jiang G, Hunter T. Curr Biol 1999;9:R568. [PubMed: 10469554]
5. Hall JM, Couse JF, Korach KS. J Biol Chem 2001;276:36869. [PubMed: 11459850]
6. Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA. Mol Endocrin 2002;16:2706.
7. Brandt ME, Vickery LE. J Biol Chem 1997;272:4843. [PubMed: 9030541]
8. Blagg BSJ, Kerr TD. Med Res Rev 2006;26:310. [PubMed: 16385472]
9. Lee JC, Strobel GA, Lobovsky E, Clardy J. J Org Chem 1996;61:3232.
10. Wagenaar MM, Clardy J. J Nat Prod 2001;64:1006. [PubMed: 11520215]
11. Marcu MG, Schulte TW, Neckers L. J Natl Can Inst 2000;92:242.
12. Burlison JA, Blagg BSJ. Org Lett 2006;8:4855. [PubMed: 17020320]
13. Posner GH, Ploypradith P, Parker MH, O'Dowd H, Woo SH, Northrop J, Krasavin M, Dolan P, Kensler TW, Xie S, Shapiro TA. J Med Chem 1999;42:4275. [PubMed: 10543871]
14. Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, Shapiro TA, Alagabala A, Foster B. J Med Chem 2004;47:1299. [PubMed: 14971910]

15. Posner GH, Paik IH, Sur S, McRiner AJ, Borstnik K, Xie S, Shapiro TA. *J Med Chem* 2003;46:1060. [PubMed: 12620083]
16. Jeyadevan JP, Bray PG, Chadwick J, Mercer AE, Byrne A, Ward SA, Park BK, Williams DP, Cosstick R, Davies J, Higson AP, Irving E, Posner GH, O'Neill PM. *J Med Chem* 2004;47:1290. [PubMed: 14971909]
17. Zheng FF, Kuduk SD, Chiosis G, Munster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. *Cancer Res* 2000;60:2090. [PubMed: 10786665]
18. Bergmann KE, Wooge CH, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. *J Steroid Biochem Mol Biol* 1994;49:139. [PubMed: 8031710]
19. Groleau S, Nault J, Lepage M, Couture M, Dallaire N, Berube G, Gaudreault RC. *Bioorg Chem* 1999;27:383.
20. Briefly, the diacid (1 equivalent) and amine (2.5 equivalents) were coupled using 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDCI, 3 equivalents) at room temperature in 30% pyridine/methylene chloride. After 12 hours, the dimers precipitated to form a colorless or yellow solid that was filtered and washed several times with methanol to provide the dimers in greater than 97% purity by ¹H NMR (Yields 16–92%).
21. Galam L, Hadden MK, Ma Z, Ye QZ, Yun BG, Blagg BSJ, Matts RL. *Bioorg Med Chem* 2007;15:1939. [PubMed: 17223347]
22. Thornber CW. *Chem Soc Rev* 1979;8:563.

Figure 1.
Structures of various natural product and synthetically prepared cytotoxic dimers.

Figure 2.
Diacids used for dimer synthesis.

Figure 3.
Amines used for dimer synthesis.

Scheme 1.
General scheme for the synthesis of **DM1-DM65**.

Table 1Anti-proliferative activity (μM) for the first two series of dimeric compounds.

Compounds	Diacid ^a	Amine ^b	MCF-7	SKBr3
Coumermycin A1	-	-	6.7 ± 0.2^c	3.2 ± 1.5
DM1	A	1	>100	>100
DM2	A	2	>100	>100
DM3	A	3	>100	>100
DM4	A	4	>100	>100
DM5	A	5	4.1 ± 0.8	2.3 ± 0.1
DM6	A	6	>100	>100
DM7	A	7	>100	>100
DM8	A	8	>100	>100
DM9	A	9	>100	>100
DM10	A	10	7.2 ± 1.8	4.5 ± 1.6
DM11	A	11	>100	>100
DM12	A	12	>100	>100
DM13	A	13	27.3 ± 8.0	28.3 ± 1.1
DM14	A	14	>100	>100
DM15	A	15	>100	>100
DM16	A	16	>100	>100
DM17	A	17	>100	>100
DM18	B	1	>100	>100
DM19	C	1	>100	>100
DM20	D	1	>100	>100
DM21	E	1	>100	>100
DM22	F	1	>100	>100
DM23	G	1	>100	>100
DM24	H	1	>100	>100
DM25	I	1	>100	>100
DM26	J	1	>100	>100
DM27	K	1	27.5 ± 8.5	>100

^a Diacid from Figure 2.^b Amines from Figure 3.^c Values are means $\pm$ standard error of two separate experiments performed in triplicate.

Table 2Anti-proliferative activity (μM) for the third series of dimeric compounds.

Compounds	Diacid ^a	Amine ^b	MCF-7	SKBr3
DM28	J	5	4.2 ± 1.3^c	10.5 ± 2.3
DM29	K	5	10.2 ± 3.5	16.3 ± 6.5
DM30	E	5	>100	>100
DM31	D	5	>100	>100
DM32	B	5	>100	>100
DM33	H	5	>100	>100
DM34	G	5	>100	>100
DM35	I	5	2.7 ± 0.2	4.5 ± 0.2

^a Diacid from Figure 2.^b Amines from Figure 3.^c Values are means $\pm$ standard error of two separate experiments performed in triplicate.

Table 3Anti-proliferative activity (μM) for the fourth series of dimeric compounds.

Compounds	Diacid ^a	Amine ^b	MCF-7	SKBr3
DM36	J	4	81.8 ± 6.7^c	>100
DM37	J	13	2.4 ± 0.4	9.0 ± 5.3
DM38	J	6	40.4 ± 3.2	87.7 ± 10.6
DM39	J	18	>100	>100
DM40	I	4	4.6 ± 2.4	15.2 ± 1.3
DM41	I	13	56.5 ± 0.2	>100
DM42	I	6	>100	>100
DM43	I	18	>100	>100
DM44	I	10	>100	>100
DM45	K	17	>100	>100
DM46	I	17	>100	>100
DM47	J	17	>100	>100
DM48	K	15	>100	>100
DM49	J	15	>100	>100
DM50	I	15	12.5 ± 1.6	>100
DM51	K	16	>100	>100
DM52	I	16	>100	>100
DM53	J	16	>100	>100

^aDiacid from Figure 2.^bAmines from Figure 3.^cValues are means $\pm$ standard error of two separate experiments performed in triplicate.

Table 4Anti-proliferative activity (μM) for the final series of dimeric compounds.

Compounds	Diacid ^a	Amine ^b	MCF-7	SKBr3
DM54	K	19	>100 ^c	>100
DM55	K	20	52.1 $\pm$ 3.5	>100
DM56	K	21	>100	>100
DM57	A	19	>100	>100
DM58	A	20	22.8 $\pm$ 5.0	34.9 $\pm$ 1.9
DM59	A	21	16.3 $\pm$ 1.5	104 $\pm$ 14
DM60	J	19	14.7 $\pm$ 0.6	>100
DM61	J	20	>100	>100
DM62	J	21	>100	>100
DM63	I	19	>100	>100
DM64	I	20	>100	>100
DM65	I	21	2.1 $\pm$ 0.8	12.2 $\pm$ 0.7

^aDiacid from Figure 2.^bAmines from Figure 3.^cValues are means $\pm$ standard error of two separate experiments performed in triplicate.